Outcomes of adults with active or progressive hematological malignancies at the time of allo-SCT: A survey from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)

Bone Marrow Transplantation

Volumn 49, Issue 3, 2014, Pages 361-365

  Chevallier, P ^a,r   Labopin, M ^b,c,d   Milpied, N ^e   Bilger, K ^f   Socie G ^g   Yakoub Agha, I ^h   Michallet, M ⁱ   Bulabois, C E ^j   Maury, S ^k   Beguin, Y ^l   Bay, J O ^m   Blaise, D ⁿ   Maillard, N ^o   Guillerm, G ^p   Daguindeau, E ^q   Raus, N ⁱ   Mohty, M ^b,c,d  

^a INSERM   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d CENTRE DE RECHERCHE SAINT ANTOINE   (France)

^e UNIVERSITÉ DE BORDEAUX   (France)

^f HÔPITAL DE HAUTEPIERRE   (France)

^g SAINT LOUIS HOSPITAL   (France)

^h LILLE UNIVERSITY HOSPITAL   (France)

ⁱ EDOUARD HERRIOT HOSPITAL   (France)

^j HÔPITAL MICHALLON   (France)

^k HENRI MONDOR HOSPITAL   (France)

^l UNIVERSITY OF LIÈGE   (Belgium)

^m UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

ⁿ INSTITUT PAOLI CALMETTES   (France)

^o POITIERS UNIVERSITY HOSPITAL   (France)

^p BREST UNIVERSITY HOSPITAL   (France)

^q UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^r HÔTEL DIEU   (France)

more..

Author keywords

allo SCT; hematological diseases; refractory; relapsed; SFGM TC

Indexed keywords

ANTINEOPLASTIC AGENT; HLA ANTIGEN;

ACUTE LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HEALTH SURVEY; HEMATOLOGIC MALIGNANCY; HLA MATCHING; HODGKIN DISEASE; HUMAN; HUMAN CELL; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MIDDLE AGED; MULTICENTER STUDY (TOPIC); MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; SIBLING; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; ADOLESCENT; ALLOTRANSPLANTATION; CHEMISTRY; CLINICAL TRIAL; FRANCE; HEMATOLOGIC NEOPLASMS; LYMPHOMA, NON-HODGKIN; MORTALITY; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROMES; MYELOPROLIFERATIVE DISORDERS; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FRANCE; HEMATOLOGIC NEOPLASMS; HLA ANTIGENS; HODGKIN DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; MYELOPROLIFERATIVE DISORDERS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RETROSPECTIVE STUDIES; SOCIETIES, MEDICAL; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84904240431     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2013.186     Document Type: Article

References (29)

1. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med 2006; 354: 1813-1826.
2. Luznik L, Fuchs EJ. Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation. Cancer Control 2012; 9: 123-137.
3. Gyurkocza B, Rezvani A, Storb RF. Allogeneic hematopoietic cell transplantation: the state of the art. Expert Rev Hematol 2010; 3: 285-299.
4. Passweg JR, Halter J, Bucher C, Gerull S, Heim D, Rovo A et al. Hematopoietic stem cell transplantation: a review and recommendations for follow-up care for the general practitioner. Swiss Med Wkly 2012; 142: w13696.
5. Passweg JR, Baldomero H, Gratwohl A, Bregni M, Cesaro S, Dreger P et al. The EBMT activity survey: 1990-2010. Bone Marrow Transplant 2012; 47: 906-923.
6. Mohty M, Labopin M, Balère ML, Socie G, Milpied N, Tabrizi R et al. Antithymocyte globulins and chronic graft-vs-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: a report from the Société Francaise de Greffe de Moelle et de Thérapie Cellulaire. Leukemia 2010; 24: 1867-1874.
7. Deeg HJ, Sandmaier BM. Who is fit for allogeneic transplantation? Blood 2010; 116: 4762-4770.
8. Ljungman P, Bregni M, Brune M, Cornelissen J, de Witte T, Dini G et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant 2010; 45: 219-234.
9. Schmid C, Schleuning M, Schwerdtfeger R, Hertenstein B, Mischak-Weissinger E, Bunjes D et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity qconditioning for allogeneic stem cell transplantation. Blood 2006; 108: 1092-1099.
10. Duval M, Klein JP, He Wensheng, Cahn JY, Cairo M, Camitta BM et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol 2010; 28: 3730-3738.
11. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695-706.
12. Fine JP, Gray RJ. A proportional hazards model for subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509.
13. Yanada M, Naoe T, Iida H, Sakamaki H, Sakura T, Kanamori H et al. Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graft-versus-host disease. Bone Marrow Transplant 2005; 36: 867-872.
14. Gratwohl A, Brand R, Apperley J, Crawley C, Ruutu T, Corradini P et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006; 91: 513-521.
15. Mohty M, Labopin M, Tabrizzi R, Theorin N, Fauser A, Rambaldi A et al. Reduced-intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Haematologica 2008; 93: 303-306.
16. Terwey TH, Massenkeil G, Tamm I, Hemmati PG, Neuburger S, Martus P et al. Allogeneic SCT in refractory or relapsed adult ALL is effective without prior reinduction chemotherapy. Bone Marrow Transplant 2008; 42: 791-798.
17. Nishiwaki S, Inamoto Y, Sakamaki H, Kurokawa M, Iida H, Ogawa H et al. Allogeneic stem cell transplantation for adult Philadelphia chromosome-negative acute lymphocytic leukemia: comparable survival rates but different risk factors between related and unrelated transplantation in first complete remission. Blood 2010; 116: 4368-4375.
18. Craddock C, Labopin M, Pillai S, Finke J, Bunjes D, Greinix H et al. Fcators predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia. Leukemia 2011; 25: 808-813.
19. Bashir Q, Khan H, Orlowski RZ, Amjad AL, Shah N, Parmar S et al. Predictors of prolongad survival alter allogeneic hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol 2012; 87: 272-276.
20. Bertz H, Illerhaus G, Veelken H, Finke J. Allogeneic hematopoietic stem-cell transplantation for patients with relapsed or refractory lymphomas: comparison of high-dose conventional conditioning versus fludarabine-based reduced-intensity regimens. Ann Oncol 2002; 13: 135-139.
21. Anderlini P, Saliba R, Acholonu S, Giralt SA, Andersson B, Ueno NT et al. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica 2008; 93: 257-264.
22. Hari P, Carreras J, Zhang MJ, Gale RP, Bolwell BJ, Bredeson CN et al. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant 2008; 14: 236-245.
23. Van Kampen RJ, Canals C, Schouten HC, Nagler A, Thomson KJ, Vernant JP et al. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing aftera n autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. J Clin Oncol 2011; 29: 1342-1348.
24. Le Gouill S, Kroger N, Dhedin N, Nagler A, Bouabdallah K, Yakoub-Agha I et al. Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experience. Ann Oncol 2012; 23: 2695-2703.
25. Detrait MY, Chevallier P, Sobh M, Guillaume T, Thomas X, Morisset S et al. Outcome of high-risk and refractory AML/MDS patients receiving a FLAMSA sequential chemotherapy regimen followed by reduced-intensity conditioning (RIC) and allogeneic hematopoietic stem cell transplantation (allo-HSCT). Blood (ASH Annual Meeting Abstracts) 2011; 118: Abstract 1957.
26. Shimoni A, Nagler A. Optimizing the conditioning regimen for allogeneic stem-cell transplantation in acute myeloid leukemia; dose intensity is still need. Best Pract Res Clin Haematol 2011; 24: 369-379.
27. Mohty M, Chevallier P. Azacitidine after allo-SCT: the good without the bad? Blood 2012; 119: 3199-3200.
28. Chevallier P, Delaunay J, Turlure P, Pigneux A, Hunault M, Garand R et al. Long term disease free survival after the MIDAM (Mylotarg, intermediaite dose Ara-C, Mitoxantrone) regimen in patients with CD33 + primary resistant or relapsed acute myeloid leukemia. J Clin Oncol 2008; 26: 5192-5197.
29. Takahashi K, Kantarjian H, Pemmaraju N, Andreeff M, Borthakur G, Faderl S et al. Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD. Br J Haematol 2013; 161: 659-666.